A Phase 3 interventional study of cabazitaxel (XRP6258) (RPR116258) and mitoxantrone in Neoplasms and Prostatic Neoplasms, sponsored by Sanofi. Completed at 26 sites in 26 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-10.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing cabazitaxel in Prostatic Neoplasms — 6 open to participants now, 10 under way, none of them phase 3. cabazitaxel · Prostatic Neoplasms.
Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, this one is the 4th largest by enrollment, is the only one that started in 2007, is one of 7 in phase 3, and was the 1st registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 46 studies testing cabazitaxel in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Case Comprehensive Cancer Center · Sites in United States
Ages 19+
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Fundacion Oncosur · Sites in Spain
Ages 18+ · Men only
Jina Pharmaceuticals Inc.
Ages 18+ · Men only
By country, each count listing its studies:
cabazitaxel: first FDA approval 2010 (JEVTANA KIT), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 32 · Phase 3 7 · Phase 4 2
First in 2007; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 755 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 60 across the 46 interventional studies. Of the 29 that completed or were terminated, 14 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 46 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
34 studies in Prostatic Neoplasms by Sanofi: none open now, none under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 34 studies in Prostatic Neoplasms by Sanofi, this one is the 5th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2007, is one of 10 in phase 3, and was the 9th registered.
Sanofi’s Prostatic Neoplasms studies by the year they started, since 2001.
2 of the studies testing cabazitaxel in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06890832Jina Pharmaceuticals Inc.A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer | 2026-12 |
| NCT06085729M.D. Anderson Cancer CenterPhase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) | 2027-09-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, from their registry updates:
Among Sanofi’s 34 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, multi-center study comparing the safety and efficacy of XRP6258 plus prednisone to mitoxantrone plus prednisone in the treatment of hormone refractory metastatic prostate cancer previously treated with a Taxotere®-containing regimen. The primary objective is overall survival. Secondary objectives include progression free survival, overall response rate, prostate-specific antigen (PSA) response/progression, pain response/progression, overall safety, and pharmacokinetics. Patients will be treated until disease progression, death, unacceptable toxicity, or for a maximum of 10 cycles. Patients will have long-term follow-up for a maximum of up to 2 years.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
This study's enrollment of 755 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Compared within Prostatic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
The investigator will evaluate whether there are other reasons why a patient may not participate.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mitoxantrone + Prednisone
Drug: mitoxantrone · Drug: prednisone
Cabazitaxel + Prednisone
Drug: cabazitaxel (XRP6258) (RPR116258) · Drug: prednisone
25 mg/m\^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle
Also known as: Jevtana
12 mg/m\^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle
10 mg daily administered by oral route
Overall Survival
Overall survival was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, the survival time was censored at the last date patient was known to be alive or at the cut-off date, whichever had come first.
Time frame: From the date of randomization up to 104 weeks (study cut-off)
Time to Progression Free Survival (PFS)
Progression free survival was defined as a composite endpoint evaluated from the date of randomization to the date of tumor progression, PSA progression, pain progression, or death due to any cause, whichever occurred first
Time frame: From the date of randomization up to 104 weeks (study cut-off)
Overall Tumor Response
Tumor Overall Response Rate (ORR) (only in patients with measurable disease): Objective responses (Complete Response and Partial Response) for measurable disease as assessed by investigators according to RECIST criteria. Complete Response (CR) is defined as: Disappearance of all target lesions. Partial Response (PR) is defined as: At least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference baseline sum LD. Confirmation of objective responses will be performed by repeat tumor imaging (CT scans, MRI, bone scans) after the first documentation of response.
Time frame: From the date of randomization up to 104 weeks (study cut-off)
Time to Tumor Progression
Time to tumor progression is defined as the number of months from randomization until evidence of progressive disease (RECIST)
Time frame: From the date of randomization up to 104 weeks (study cut-off)
Time to Prostatic Specific Antigen (PSA) Progression
In PSA non-responders, progression will be defined as a 25% increase over nadir and increase in the absolute value PSA level by at least 5 ng/ml and confirmed by a second value at least 4 weeks later. In PSA responders and in patients not evaluable for PSA response at baseline, progression will be defined as a ≥50% increase over nadir, provided that the increase is a minimum of 5 ng/ml and confirmed by a second value at least 1 week later.
Time frame: at screening, day 1 of every treatment cycle, up to 104 weeks (study cut-off)
PSA (Prostate-Specific Antigen) Response
PSA response was defined as a ≥ 50% reduction in serum PSA, determined only for patients with a serum PSA ≥ 20ng/mL at baseline, confirmed by a repeat PSA ≥ 3 weeks later.
Time frame: from baseline up to 104 weeks (study cut-off)
Time to Pain Progression
Pain Progression is defined as an increase of ≥1 point in the median Personal Pain Intensity (PPI) from its nadir noted on 2 consecutive 3-week-apart visits or ≥25 % increase in the mean analgesic score compared with the baseline score \& noted on 2 consecutive 3-week-apart visits or requirement for local palliative radiotherapy. Evaluation of the PPI \& analgesic scores are based on the short-form McGill Pain Questionnaire which consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0=none (best) 1=mild 2=moderate 3=severe (worst) (TOTAL: 0=best 45=worst)
Time frame: from baseline up to 104 weeks (study cut-off)
Pain Response
Pain Response was defined as a two-point or greater reduction from baseline median Present Pain Intensity (PPI) score without an increased Analgesic Score (AS) or a decrease of ≥50% in the AS without an increase in the PPI score, maintained for at least 3 weeks.
Time frame: from baseline up to 104 weeks (study cut-off)
Multicenter study: 146 actives sites from 26 countries in Europe, USA, South America and Asia Pacific region. Study initiation date: January 2nd, 2007; study completion date/study cut off date: September 25th, 2009.
| Milestone | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone |
|---|---|---|
| Started | 377 | 378 |
| Completed | 46 | 105 |
| Not completed | 331 | 273 |
| Withdrew: Disease progression | 267 | 180 |
| Withdrew: Adverse event | 32 | 67 |
| Withdrew: Non-compliance to protocol | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Withdrawal by subject | 17 | 8 |
| Withdrew: Not treated | 6 | 7 |
| Withdrew: Screened failure | 2 | 1 |
| Withdrew: Investigator's decision | 1 | 4 |
| Withdrew: Non-confirmed disease progression | 1 | 1 |
| Withdrew: Clinical deterioration | 1 | 0 |
| Withdrew: Screening error | 2 | 1 |
| Withdrew: Withdrawal by subject's family | 0 | 1 |
| Withdrew: Patient unable to come to the clinic | 0 | 1 |
| Withdrew: Abnormal liver function tests | 0 | 1 |
Overall survival was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, the survival time was censored at the last date patient was known to be alive or at the cut-off date, whichever had come first.
| Months | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone |
|---|---|---|
| Overall Survival | 12.7 (11.6 to 13.7) | 15.1 (14.1 to 16.3) |
Progression free survival was defined as a composite endpoint evaluated from the date of randomization to the date of tumor progression, PSA progression, pain progression, or death due to any cause, whichever occurred first
| Months | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone |
|---|---|---|
| Time to Progression Free Survival (PFS) | 1.4 (1.4 to 1.7) | 2.8 (2.4 to 3.0) |
Tumor Overall Response Rate (ORR) (only in patients with measurable disease): Objective responses (Complete Response and Partial Response) for measurable disease as assessed by investigators according to RECIST criteria. Complete Response (CR) is defined as: Disappearance of all target lesions. Partial Response (PR) is defined as: At least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference baseline sum LD. Confirmation of objective responses will be performed by repeat tumor imaging (CT scans, MRI, bone scans) after the first documentation of response.
| percentage of participants | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone |
|---|---|---|
| Overall Tumor Response | 4.4 (1.6 to 7.2) | 14.4 (9.6 to 19.3) |
Time to tumor progression is defined as the number of months from randomization until evidence of progressive disease (RECIST)
| Months | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone |
|---|---|---|
| Time to Tumor Progression | 5.4 (4.7 to 6.5) | 8.8 (7.4 to 9.6) |
In PSA non-responders, progression will be defined as a 25% increase over nadir and increase in the absolute value PSA level by at least 5 ng/ml and confirmed by a second value at least 4 weeks later. In PSA responders and in patients not evaluable for PSA response at baseline, progression will be defined as a ≥50% increase over nadir, provided that the increase is a minimum of 5 ng/ml and confirmed by a second value at least 1 week later.
| Months | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone |
|---|---|---|
| Time to Prostatic Specific Antigen (PSA) Progression | 3.1 (2.2 to 4.4) | 6.4 (5.1 to 7.3) |
PSA response was defined as a ≥ 50% reduction in serum PSA, determined only for patients with a serum PSA ≥ 20ng/mL at baseline, confirmed by a repeat PSA ≥ 3 weeks later.
| Percentage of participants | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone |
|---|---|---|
| PSA (Prostate-Specific Antigen) Response | 17.8 (13.7 to 22.0) | 39.2 (33.9 to 44.5) |
Pain Progression is defined as an increase of ≥1 point in the median Personal Pain Intensity (PPI) from its nadir noted on 2 consecutive 3-week-apart visits or ≥25 % increase in the mean analgesic score compared with the baseline score \& noted on 2 consecutive 3-week-apart visits or requirement for local palliative radiotherapy. Evaluation of the PPI \& analgesic scores are based on the short-form McGill Pain Questionnaire which consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0=none (best) 1=mild 2=moderate 3=severe (worst) (TOTAL: 0=best 45=worst)
| Months | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone |
|---|---|---|
| Time to Pain Progression | NA (NA to NA) | 11.1 (8.1 to NA) |
Pain Response was defined as a two-point or greater reduction from baseline median Present Pain Intensity (PPI) score without an increased Analgesic Score (AS) or a decrease of ≥50% in the AS without an increase in the PPI score, maintained for at least 3 weeks.
| Percentage of participants | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone |
|---|---|---|
| Pain Response | 7.7 (3.7 to 11.8) | 9.2 (4.9 to 13.5) |
Collected over Adverse events are collected from the time to the first patient signed an informed consent form until 30 days after the administration of the last cycle of the study treatment to the last patient (i.e. 104 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mitoxantrone + Prednisone | — | 77/371 (20.8%) | 323/371 (87.1%) |
| Cabazitaxel + Prednisone | — | 145/371 (39.1%) | 350/371 (94.3%) |
| Event | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 4/371 | 25/371 |
| NeutropeniaBlood and lymphatic system disorders | 3/371 | 18/371 |
| Disease progressionGeneral disorders | 11/371 | 1/371 |
| HaematuriaRenal and urinary disorders | 3/371 | 10/371 |
| DiarrhoeaGastrointestinal disorders | 0/371 | 9/371 |
| VomitingGastrointestinal disorders | 2/371 | 6/371 |
| Abdominal painGastrointestinal disorders | 0/371 | 6/371 |
| PyrexiaGeneral disorders | 1/371 | 6/371 |
| PneumoniaInfections and infestations | 2/371 | 6/371 |
| Renal failureRenal and urinary disorders | 0/371 | 6/371 |
| Event | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 39/371 | 170/371 |
| FatigueGeneral disorders | 102/371 | 136/371 |
| NauseaGastrointestinal disorders | 84/371 | 127/371 |
| VomitingGastrointestinal disorders | 36/371 | 80/371 |
| AstheniaGeneral disorders | 46/371 | 76/371 |
| ConstipationGastrointestinal disorders | 56/371 | 73/371 |
| NeutropeniaBlood and lymphatic system disorders | 38/371 | 66/371 |
| AnorexiaMetabolism and nutrition disorders | 39/371 | 59/371 |
| Back painMusculoskeletal and connective tissue disorders | 41/371 | 58/371 |
| HaematuriaRenal and urinary disorders | 13/371 | 58/371 |
| Age Continuous(years) | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone | Total |
|---|---|---|---|
| Median | 67.0 (47 to 89) | 68.0 (46 to 92) | 67 (46 to 92) |
| Sex/Gender, Customized(participants) | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone | Total |
|---|---|---|---|
| Male | 377 | 378 | 755 |
| Region of Enrollment(participants) | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone | Total |
|---|---|---|---|
| United States | 106 | 97 | 203 |
| Taiwan | 4 | 7 | 11 |
| Slovakia | 1 | 1 | 2 |
| Spain | 10 | 9 | 19 |
| Chile | 9 | 12 | 21 |
| Russian Federation | 6 | 4 | 10 |
| Italy | 17 | 18 | 35 |
| India | 11 | 9 | 20 |
| France | 44 | 46 | 90 |
| Denmark | 19 | 26 | 45 |
| South Africa | 7 | 9 | 16 |
| Netherlands | 8 | 9 | 17 |
| Korea, Republic of | 8 | 7 | 15 |
| Finland | 4 | 1 | 5 |
| Turkey | 17 | 19 | 36 |
| United Kingdom | 17 | 20 | 37 |
| Hungary | 8 | 7 | 15 |
| Czech Republic | 10 | 12 | 22 |
| Mexico | 2 | 3 | 5 |
| Canada | 16 | 16 | 32 |
| Argentina | 7 | 3 | 10 |
| Brazil | 7 | 4 | 11 |
| Belgium | 16 | 15 | 31 |
| Singapore | 6 | 3 | 9 |
| Germany | 6 | 11 | 17 |
| Sweden | 11 | 10 | 21 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone | Total |
|---|---|---|---|
| 0 - Fully Active | 120 | 141 | 261 |
| 1 - Ambulatory, Restricted Activity | 224 | 209 | 433 |
| 2 - Ambulatory, No Work Activities | 33 | 28 | 61 |
| Prostatic Specific Antigen PSA(ng/mL) | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone | Total |
|---|---|---|---|
| Median | 127.5 (2 to 11220) | 143.9 (2 to 7842) | 135.00 (2 to 11220) |
| Measurable disease(Participants) | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone | Total |
|---|---|---|---|
| Measurable disease | 204 | 201 | 405 |
| Not Measurable disease | 173 | 177 | 350 |
| Extent of disease(Participants) | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone | Total |
|---|---|---|---|
| Metastatic | 356 | 364 | 720 |
| Locoregional Recurrence | 20 | 14 | 34 |
| Missing | 1 | 0 | 1 |
| Tumor Location: number of sites involved(Participants) | Mitoxantrone + Prednisone | Cabazitaxel + Prednisone | Total |
|---|---|---|---|
| 1 | 134 | 146 | 280 |
| 2 | 117 | 112 | 229 |
| 3 | 78 | 73 | 151 |
| 4 or more | 43 | 44 | 87 |
| Missing | 5 | 3 | 8 |
The record gives a start of Jan 2007, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabazitaxel